【摘要】 目的 探讨卡瑞丽珠单抗联合GP化疗治疗非小细胞肺癌（NSCLC）的效果。方法 选取2019年6月至2021年2月安徽省马鞍山市人民医院收治的62例NSCLC患者为研究对象，依照随机抽签法分为单一组和联合组，各31例。单一组采用GP化疗治疗，联合组采用卡瑞丽珠单抗与GP化疗联合治疗。比较两组临床疗效。比较两组治疗前与治疗6个周期的肺功能指标[用力肺活量（FVC）、第1秒用力呼气容积（FEV1）、最大通气量（MVV）]、免疫功能指标（CD4+、CD3+、CD8+）。结果 联合组临床疗效优于单一组，差异有统计学意义（P <0.05）。治疗6个周期，两组FVC、FEV1、MVV均高于治疗前，且联合组高于单一组，差异有统计学意义（P <0.05）。治疗6个周期，两组CD4+、CD3+水平均高于治疗前，CD8+水平低于治疗前，且联合组CD4+、CD3+水平均高于单一组，CD8+水平低于单一组，差异有统计学意义（P <0.05）。结论 卡瑞丽珠单抗联合GP化疗治疗NSCLC效果显著，能改善患者肺功能与免疫功能。更多还原

【Abstract】 Objective To investigate the effect of Camrelizumab combined with GP chemotherapy in the treatment of non-small cell lung cancer(NSCLC). Methods A total of 62 patients with NSCLC admitted to Maanshan People’s Hospital of Anhui Province from June 2019 to February 2021 were selected as the research subjects, and they were divided into single group and combined group according to random drawing, with 31 cases in each group. The single group was treated with GP chemotherapy, and the combined group was treated with Camrelizumab combined with GP chemotherapy. Clinical effects of two groups were compared. The indexes of pulmonary function(forced vital capacity[FVC], forced expiratory volume in the first second [FEV1], maximum ventilation volume [MVV], and immune function(CD4+, CD3+, CD8+) were compared between two groups before treatment and six cycles of treatment. Results Clinical effect of combined group was better than that of single group, and the difference was statistically significant(P < 0.05).Six cycles of treatment, FVC, FEV1, and MVV in two groups were higher than those before treatment, and those in combined group were higher than those in single group, the differences were statistically significant(P < 0.05). Six cycles of treatment, the levels of CD4+and CD3+in two groups were higher than those before treatment, and the levels of CD8+in two groups were lower than those before treatment(P < 0.05), and the levels of CD4+and CD3+in combined group were higher than those in single group, and the level of CD8+in combined group was lower than that in single group, the differences were statistically significant(P < 0.05). Conclusion Camrelizumab combined with GP chemotherapy has a significant effect in the treatment of NSCLC, and can improve the lung function and immune function of patients.更多还原